Aspire Biopharma Holdings, Inc. ASBP
is an early-stage biopharmaceutical company. As a Delaware corporation formed in February 2025, the Company engages in the business of
developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business
Combination we were a privately held Puerto Rico corporation incorporated in September 2021. Our internet address is www.aspirebiolabs.com.
expect to generate revenue through developing and marketing drugs and nutraceuticals using the technology for the novel sublingual delivery.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.2K | — | — | — | — | — |
| Cost of revenue | $6.3K | — | — | — | — | — |
| Gross profit | -$116 | — | — | — | — | — |
| R&D | $923.9K | $144.4K | — | — | — | — |
| SG&A | $17.6M | $940.4K | $1.3M | $976.3K | — | — |
| Total operating expenses | $19.4M | $1.2M | $1.3M | $976.3K | — | — |
| Operating income | -$19.4M | -$1.2M | — | — | — | — |
| Interest expense | $8.5M | $98.0K | — | — | — | — |
| Pre-tax income | -$24.5M | -$1.3M | — | — | — | — |
| Income tax | — | $1.0K | — | — | — | — |
| Net income | -$24.5M | -$1.3M | $4.5M | $3.3M | — | — |
| EPS, diluted | -16.38 | -1.90 | — | — | — | — |
| Shares, diluted (wtd. avg.) | $1.5M | $689.9K | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.0M | $3.6K | $11.2K | $497.3K | — | — |
| Inventory | $253.2K | — | — | — | — | — |
| Total current assets | $1.3M | $148.0K | $81.2K | $1.1M | $293.2K | — |
| Total assets | $1.3M | $148.0K | $20.0M | $300.2M | $293.2K | — |
| Accounts payable | $1.0M | $310.2K | $152.0K | $180.6K | $273 | — |
| Total current liabilities | $7.6M | $1.7M | $403.3K | $303.3K | $293.7K | — |
| Total liabilities | $7.7M | $1.7M | $403.3K | $11.1M | $293.7K | — |
| Retained earnings | -$27.3M | -$2.8M | -$11.3M | -$9.9M | -$25.5K | — |
| Total equity | -$6.4M | -$1.5M | -$487.9K | -$9.9M | -$475 | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.9M | -$265.2K | -$653.1K | -$1.4M | — | — |
| Stock-based compensation | $14.1M | — | — | — | — | — |
| Investing cash flow | — | $13.8M | $284.9M | -$294.7M | — | — |
| Financing cash flow | $5.9M | $257.6K | -$284.8M | $296.6M | — | — |
| Buybacks | — | $13.8M | $284.9M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-016123.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |